申请人:SUMITOMO DAINIPPON PHARMA ONCOLOGY INC
公开号:WO2021067772A1
公开(公告)日:2021-04-08
Formulations of Compound 1 or a pharmaceutically acceptable salt thereof are described. Also disclosed are capsules having a dry blended powder comprising Compound 1 or a pharmaceutically acceptable salt thereof. The Compound 1 or a pharmaceutically acceptable salt thereof may be a tartrate salt of Compound 1, such as a mono-, sub-, or di-tartrate salt, and including crystalline forms thereof. The formulations may include excipients such as diluents (e.g., microcrystalline cellulose, lactose); disintegrants (e.g., croscarmellose sodium); and lubricants (e.g., magnesium stearate).
化合物1或其药用可接受盐的配方已被描述。还披露了含有干混合粉末的胶囊,该粉末包括化合物1或其药用可接受盐。化合物1或其药用可接受盐可以是化合物1的酒石酸盐,例如单酒石酸盐、亚酒石酸盐或双酒石酸盐,包括其结晶形式。这些配方可能包括赋形剂,如稀释剂(例如微晶纤维素、乳糖);分散剂(例如交联羧甲纤维素钠);和润滑剂(例如硬脂酸镁)。